Jean Charles Soria
About Jean Charles Soria
Jean-Charles Soria is the Senior Vice President of Research and Development at Amgen and serves on the American Association for Cancer Research Board of Directors for the 2024-2027 term.
Jean-Charles Soria's Role at Amgen
Jean-Charles Soria serves as the Senior Vice President of Oncology within Global Development at Amgen. His responsibilities include overseeing research and development activities, particularly in the field of oncology. His work contributes to the company's ongoing efforts to develop targeted therapies for cancer.
American Association for Cancer Research Board of Directors
Jean-Charles Soria has been elected to the American Association for Cancer Research (AACR) Board of Directors for the 2024-2027 term. His election to this prestigious position highlights his significant contributions and leadership in the field of cancer research.
Editorial Contributions to AACR Journals
Jean-Charles Soria actively contributes to AACR's peer-reviewed journals. He serves as a scientific editor for Cancer Discovery and as a deputy editor for Clinical Cancer Research. These roles involve overseeing the review process and guiding the development of high-impact research publications in the oncology field.
Involvement in AACR Committees and Task Forces
Jean-Charles Soria sits on the AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research Committee. He has also been vice chair of the Annual Meeting Program Committee for the AACR and has served as an industry member of the AACR Exploratory IND/Phase 0 Clinical Trials Task Force and a member of the AACR COVID-19 and Cancer Task Force.
Educational Background and Expertise
Jean-Charles Soria holds both an MD and a PhD, establishing a strong foundation for his work in medical and clinical research. His educational qualifications have equipped him to advance in the field of oncology, with a particular focus on the development of targeted therapies. He is committed to exploring the potential of targeting FGFR2b protein overexpression in gastric cancer.